KITCHENER, ON, MAY 11, 2023 ¬– Scispot, the creator of the best tech stack for modern biotech, announces its partnership with Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery.
This collaboration aims to empower Indee Labs to digitalize and centralize their research and development processes, leveraging Scispot's no-code operating platform for enhanced efficiency, compliance, and automation, enabling them to operate as a true Digital Biotech company.
Scispot unifies the core functionalities of Electronic Lab Notebook (ELN) and Laboratory Information Management System (LIMS) in a single platform while offering seamless one-click integrations with hundreds of 3rd-party apps and instruments. The platform streamlines repeatable workflows, automates redundant tasks, and generates valuable insights for improved R&D decisions. With Scispot, Indee Labs and other Scispot customers can efficiently meet stringent compliance requirements, such as HIPAA, SOC 2, and CFR Part 11, ensuring a secure and compliant research environment.
Indee Labs’ groundbreaking Hydropore™ platform enables non-viral intracellular delivery to modify mammalian T cells without viral vectors. Adopting Scispot’s tech stack allows Indee Labs to optimize their workflow and concentrate on advancing immune cell research.
“We’re thrilled to partner with Indee Labs and support their innovative work in immunotherapy,” said Guru Singh, founder & CEO of Scispot. “Our platform's automation, advanced analytics, and visualization tools will streamline workflows, improve data management, and propel scientific progress.”
“Scispot’s no-code digital operating platform will greatly streamline our R&D processes, enabling our team to focus on what truly matters - advancing immunotherapy research,” says Ryan Pawell, CEO of Indee Labs. “Not only does Scispot perfect our internal technical operations, but the seamless integration and automation capabilities offered by Scispot make it a lot easier to operate as a distributed biotech company.”
Indee Labs’ partnership with Scispot highlights their dedication to innovation and optimization across all aspects of research and development. Supported by funding from IndieBio/SOSV, Y Combinator, Social Capital, Founders Fund, and the National Institutes of Health, Indee Labs has attracted attention from top pharmaceutical companies, life science and biotechnology organizations, and renowned academic institutions such as UCSF, Medical University of South Carolina, and Stanford.
Scispot has become the preferred tech stack for modern biotech startups and scaleups worldwide. On a mission to transform biotech companies into Digital Biotechs, Scispot eliminates data silos, streamlines R&D, and automates processes. With hundreds of integrations, connectors for 3rd-party apps and instruments, and powerful data transformation and analytics capabilities, Scispot helps biotech companies accelerate scientific breakthroughs and bring innovations to market faster.
ABOUT SCISPOT
Scispot is a Y Combinator-backed life science informatics company based in the Kitchener-Waterloo area. Scispot has created the best tech stack to help modern biotechs evolve into efficient, scalable TechBio companies. Scispot’s toolkit makes biotech R&D templatizable and programmable, enabling companies to automate lab management, centralize data, establish repeatable workflows, and comply with regulatory guidelines. To learn more, please visit http://www.scispot.com.
ABOUT INDEE LABS
Indee Labs is a biotechnology startup developing Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers, and a small footprint. The team at Indee Labs works with three of the top ten pharmaceutical companies, various life-science and biotechnology companies, along with UC San Francisco and the Medical University of South Carolina. Indee Labs is backed by IndieBio/SOSV, Y Combinator, Social Capital, and Founders Fund, among others. More information is available at indeelabs.com.
